Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL.

Seunggyu Kim, Joonha Park, Jeongsik Kim, Jessie S Jeon

ACS biomaterials science & engineering 2021 Mar 08

filter terms:

Fas ligand (FasL, CD178) is known to bind to its receptor (Fas, CD95) and mediate cellular apoptosis to maintain immune homeostasis. Recently, it has been recognized that tumor cells and their microenvironments allow an adjacent vascular endothelium to express the FasL on its cell membrane, utilizing the endothelium as an immune barrier to kill antitumor cytotoxic T cells. Here, a microfluidic tumor vasculature model is presented, which enables the recapitulation of an endothelial immune barrier expressing FasL. The in vitro three-dimensional model replicates enhanced endothelial FasL expression under the hypoxic tumor microenvironment. Apoptosis rates of FasL-susceptible target cells are augmented under the microenvironment with upregulated FasL but are consequently abrogated by administrations of pharmacological inhibitions, FasL-Fas blockades. The microfluidic system suggests its promising applications in elucidating complex immunosuppressive mechanisms of the tumor microenvironment and screening of cell-mediated immunotherapies as a preclinical model.

Citation

Seunggyu Kim, Joonha Park, Jeongsik Kim, Jessie S Jeon. Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL. ACS biomaterials science & engineering. 2021 Mar 08;7(3):1230-1241